Infectious etiology of vasculitis: Diagnosis and management
Tóm tắt
Vasculitides are a heterogeneous group of syndromes characterized by inflammation of the vessel wall. Several microbial pathogens have been known or suspected to cause vasculitis, and the development of molecular biology has promoted the search and confirmation of infectious agents in idiopathic vasculitis. Though several agents present primarily as an infectious process with vasculitis as an occasional manifestation, vasculitis may be the major manifestation of disease. Less definitive, and more controversial, is the role of infection and inflammation of the vessel wall in the pathogenesis of atherosclerotic disease. Clinical features can be nonspecific, and a high index of suspicion is required in order to make a diagnosis of vasculitis. Infection should always be excluded based on appropriate cultures and serologic assays, and, if confirmed, early and aggressive treatment should be instituted. However, in many instances, especially if there is a delay in the diagnosis, surgical intervention becomes necessary to treat the associated anatomic and physiologic sequelae.
Tài liệu tham khảo
Naides SJ: Known causes of vasculitis in man. Cleve Clin J Med 2002, 69(suppl):15–23. Comprehensive review of infectious agents that cause vasculitis.
Trepo C, Guillevin L: Polyarteritis nodosa and extrahepatic manifestation of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun 2001, 16:269–274.
Vassilopoulos D, Calabrese LH: Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapy. Arthritis Rheum 2002, 46:585–597. Comprehensive and most clinically relevant review of the treatment of hepatitis C infection and its extra-hepatic manifestations.
Cohen Tervaert JW, Popa ER, Bos NA: The role of superantigens in vasculitis. Curr Opin Rheumatol 1999, 11:24–33.
Aggarwal A, Chag M, Sinha N, Naik S: Takayasu’s arteritis: role of Mycobacterium tuberculosis and its 65kDa heat shock protein. Int J Cardiol 1996, 55:49–55.
Kerr GS: Takayasu’s arteritis. Rheum Dis Clin North Am 1995, 21:1041–1058.
Duhaut P, Bosshard S, Calvet A, et al.: Giant cell arteritis, polymyalgia rheumatica, and viral hypothesis: a multicenter, prospective case-control study. J Rheumatol 1999, 26:361–369.
Gabriel SE, Espy M, Erdman DD, et al.: The role of parvovirus B19 in the pathogenesis of giant cell arteritis. Arthritis Rheum 1999, 42:1255–1258.
Helweg-Larsen J, Tarp B, Obel N, Baslund B: No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology 2002, 41:445–449.
Regan MJ, Wood BJ, Hsieh YH, et al.: Temporal arteritis and Chlamydia pneumoniae: failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls. Arthritis Rheum 2002, 46:1056–1060.
Popa ER, Stegeman CA, Kallenberg CGM, Cohen-Tervaert JW: Staphylococcus aureus and Wegener’s granulomatosis. Arthritis Res 2002, 4:77–79.
Cohen Tervaert JW, Stegeman CA, Kallenberg CG: Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. Current Opin Nephrol Hypertens 2001, 10:211–217.
Sangle S, Karim MY, Hughes GRV, D’Cruz DP: Sulphamethoxazole-trimethoprim in the treatment of limited paranasal Wegener’s granulomatosis. Rheumatology 2002, 41:589–590.
Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996, 335:16–20.
Cohen Tervaert JW: Infections in primary vasculitides. Cleve Clin J Med 2002, 69(suppl):24–26.
Shingadia D, Bose A, Booy R: Could a herpesvirus be the cause of Kawasaki disease? Lancet Infect Dis 2002, 2:310–313.
Saulsbury FT: Epidemiology of Henoch-Schonlein purpura. Cleve Clin J Med 2002, 69(suppl):87–89.
Ayoub EM, McBride J, Schmiederer M, Anderson B: Role of Bartonella henselae in the etiology of Henoch-Schonlein purpura. Pediatr Infect Dis J 2002, 21:28–31.
Liuzzo G, Biascucci LM, Gallimore JR, et al.: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994, 331:417–24.
Koenig W, Sund M, Frohlich M, et al.: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237–242.
Numano F: Vasa vasoritis, vasculitis and atherosclerosis. Int J Cardiol 2000, 75:S1-S8. Excellent overview of the relationship between inflammation, human leukocyte antigen, autoimmune mechanisms, and atherosclerosis.
Espinola-Klein C, Rupprecht HJ, Blankenbert S, et al.: Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002, 105:15–21.
Ridker PM: On evolutionary biology, inflammation, infection and the causes of atherosclerosis. Circulation 2002, 105:2–4. Cogent editorial of the interrelation of the factors in the pathogenesis of atherosclerosis.
Muhlestein JB, Anderson JL, Carlquist JF, et al.: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000, 12:1755–1760.
Filer A, Hughes A, Kane K, et al.: Successful treatment of hepatitis B-associated vasculitis using lamivudine as the sole therapeutic agent. Rheumatology (Oxford) 2001, 40:1064–1065.
Deleaval P, Stadler P, Descombes E, et al.: Life-threatening complication of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2-b therapy: successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids. Clin Rheumatol 2001, 20:290–292.
Shibolet O, Ilan Y, Gillis S, et al.: Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002, 100:391–396.
DeRemee RA, McDonald TJ, Weiland LH: Wegener’s granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985, 60:27–32.
Presti RM, Pollock JL, Dal Canto AJ, et al.: Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med 1998, 188:577–588.
Dal Canto AJ, Swanson PE, O’Guin AK, et al.: IFN-gamma action I the media of the great elastic arteries, a novel immunoprivileged site. J Clin Invest 2001, 107:R15-R22.
Zeuzem S, Feinman SV, Rasenack J, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666–1672.
Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673–1680.
Campbell S, Ghosh S: Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001, 13:191–192.
Prichard C: Etanercept and hepatitis C. J Clin Rheumatol 1999, 5:179–180.
Zaja F, Russo D, Fuga G, et al.: Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999, 84:1157–1158.